Will Ribociclib be included in medical insurance in 2025?

Ribociclib (Ribociclib), as a CDK4/6 inhibitor for the targeted treatment of breast cancer, has completed the dual progress of marketing and medical insurance access in China in recent years. Currently, the drug has been included in the national medical insurance catalog. Its indications are mainly for patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. It is especially recommended to be combined with an aromatase inhibitor as one of the initial endocrine treatment options for female patients.

From a medical insurance perspective, inclusion means that the actual medication burden for most patients is significantly reduced. When the original drug was first launched, the price was relatively high, and ordinary patients often faced financial pressure. However, after entering the medical insurance catalog, the reimbursement ratio increased significantly, allowing more people to receive standardized treatment in the early stages of the disease. The actual implementation scope of medical insurance coverage will vary slightly depending on regional policies, but the overall trend is to encourage patients to receive first-line treatment recommended by international guidelines, thereby improving survival benefits.

The entry of Riboxil into medical insurance will also help optimize the overall treatment pattern of breast cancer. In the past, some patients may choose more traditional chemotherapy methods due to cost reasons. Although they can relieve symptoms in the short term, they have severe side effects and limited long-term survival advantages. Nowadays, with the support of medical insurance, the combined model of targeting and endocrine therapy is gradually becoming mainstream, which is consistent with the clinical practice in European and American countries, and also represents the gradual integration of domestic breast cancer treatment with international standards.

It needs to be emphasized that medical insurance access does not mean that all patients are suitable for using this drug. The use of Riboxil still relies on molecular typing test results. Only HR-positive and HER2-negative groups are eligible for medical insurance reimbursement. In addition, blood and electrocardiograms need to be monitored during drug use to avoid potential risks

Reference materials:https://us.kisqali.com/